NBIX Neurocrine Biosciences, Inc. - Common Stock
NASDAQ · Biotechnology · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Jul 31, 2026
$143.18
· of 52w range
· above low
· to high
$123.0052w low
$186.1252w high
Market Cap (MRQ)
$14.55B
P/E (TTM)
21.0
EPS (TTM)
$6.83
Revenue (TTM)
$3.37B
your badges
52W Range
$123–$186
Analyst Rating
BUY
Price Target
$208
P/E
21.0
ROE
22.1%
Net Profit Margin
20.9%
Your badge strip is empty — pin a metric anywhere on this page.
NBIX Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$143.18
Market Cap (MRQ)
$14.55B
P/E (TTM)
21.0
EPS (TTM)
$6.83
Revenue (TTM)
$3.37B
ROE (TTM)
22.1%
52W Range
$123–$186
NBIX Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
About Neurocrine Biosciences, Inc. - Common Stock Company overview from Wikipedia
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids.
History
Neurocrine was founded in San Diego, California, in 1992. The company's academic founders were Wylie Vale of the Salk Institute for Biological Studies, and Lawrence Steinman of Stanford University. The company was backed and organized by Larry Bock of Avalon Ventures among others.
In 1995, the company collaborated with Belgium-based Janssen Pharmaceutica N.V. to develop treatments for psychiatric disorders utilizing corticotropin releasing factor (CRF) antagonists, a class of compounds to treat psychiatric, neurological and gastrointestinal diseases including anxiety, depression and irritable bowel syndrome. The company underwent an IPO in May 1996, listing on the NASDAQ exchange under the symbol NBIX and raising $34.2 million.
In October 1996, Eli Lilly and Company agreed to pay Neurocrine $74 million over five years to develop drugs for obesity and Alzheimer's disease based on its research of CRF-binding protein-ligand inhibitors.
In July 2001, Neurocrine and GlaxoSmithKline entered into a worldwide research, development and commercialization agreement, including a collaborative research program for up to five years to identify and develop CRF-R antagonist compounds. The collaboration also included worldwide development and commercialization of NBI-34041 as well as potential backup candidates resulting from the research program. Neurocrine received upfront fees and early milestone payments totaling $25.5 million.
In December 2002, Neurocrine reached an agreement with Pfizer for the rights to its experimental insomnia drug, indiplon. The deal paid Neurocrine $100 million initially with a possible $300 million more if the drug met regulatory and sales goals. In May 2006, the FDA issued a non-approvable letter for a modified-release 15 mg formulation of indiplon and an approvable letter with stipulations for 5 mg and 10 mg immediate-release formulations. As a result, Pfizer terminated its agreement with Neurocrine. Following a resubmission of the 5 mg and 10 mg formulations in December 2007, Neurocrine's new drug application was deemed 'approvable' but the FDA requested additional studies. The company discontinued development of the drug in the United States. In 2007, Neurocrine partnered with Dainippon Sumitomo Pharma to develop and commercialize indiplon in Japan. The deal paid Neurocrine $20 million up front with the ability to receive milestone payments and royalties based on the commercialization of indiplon in Japan.
Kevin Gorman replaced Gary Lyons as CEO of the company in January 2008. Lyons was CEO and president of the company since its founding and maintained a role on the company's board of directors.
On June 16, 2010, Neurocrine agreed to a deal with AbbVie Inc. (previously Abbott Laboratories) worth up to $575 million with Neurocrine granting AbbVie the worldwide rights to develop and commercialize elagolix, an oral gonadotropin-releasing hormone (GnRH) antagonist to treat endometriosis and uterine fibroids. The deal paid Neurocrine $75 million up front.
In April 2017, the FDA approved valbenazine for the treatment of TD. At the time of approval, it was the first and only drug approved for adults with TD. Neurocrine is also studying valbenazine in clinical trials for the treatment of Tourette Syndrome. In October 2017, Neurocrine announced that it had been granted orphan drug designation status from the FDA for valbenazine for the treatment of pediatric patients with Tourette syndrome.
In February 2017, Neurocrine announced an exclusive licensing agreement for the development and commercialization of the Parkinson's disease drug, opicapone, in North America with the Portugal-based pharmaceutical company Bial. As part of the agreement, Neurocrine provided an upfront payment of $30 million and agreed to fund development activities for FDA approval in the United States. Bial is eligible to receive additional milestone payments of up to $115 million and a percentage of net sales.
In September 2017, AbbVie submitted a NDA to the FDA for elagolix for the management of endometriosis and associated pain. The submission was supported by two similar Phase 3 clinical studies involving 1,700 women. In October 2017, AbbVie and Neurocrine announced that the FDA granted priority review for the elagolix NDA. A final regulatory decision on the drug will come during the third quarter of 2018. The companies are also developing elagolix for the treatment of uterine fibroids which is in Phase III development.
In 2021,Nexera Pharmain Japan licensed out its investigational schizophrenia drug, NBI-1117568, to Neurocrine Biosciences for development.
In August 2024, Neurocrine announced the results of a Phase II clinical trial of NBI-1117568 . The drug demonstrated a 7.5-point improvement in the Positive and Negative Syndrome Scale (PANSS), which was lower than the 8.4-point improvement seen with KarXT (developed by Karuna Therapeutics) and the 12.7-point improvement seen with Emraclidine (developed by Cerevel Therapeutics), both of which were also in clinical trials at the time. Additionally, the study found no dose-dependent response to NBI-1117568. As a result, Neurocrine's stock price fell 19% the following day as investors were disappointed by the results.
Product pipeline
Elagolix – gonadotropin-releasing hormone receptor antagonist undergoing FDA review for the treatment of endometriosis and in clinical trials for uterine fibroids
Opicapone – A once daily catechol-O-methyl transferase inhibitor in trials for Parkinson's disease
NBI-74788 – Corticotropin-releasing factor (CRF) receptor antagonist
NBI-1117568 - A drug that stimulates muscarinic receptors and is used to treat schizophrenia.
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
sectorHealthcare
industryBiotechnology
employees2,500
countryUS
10-Year Performance Revenue, net income, margins and EPS trends
Revenue$2.86B2016-12-31 → 2025-12-31
EPS$4.672016-12-31 → 2025-12-31
Free Cash Flow$749M2016-12-31 → 2025-12-31
Net margin20.9%2016-12-31 → 2025-12-31
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | NBIX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E (TTM) | 21.05Y avg ≈58.9 | ≈58.9 | 19.4 | Overvalued | |
| P/S (TTM) | 4.35Y avg ≈6.5 | ≈6.5 | 7.3 | Undervalued | |
| P/B (MRQ) | 3.95Y avg ≈5.6 | ≈5.6 | 14.5 | Undervalued | |
| Price / FCF (TTM) | 16.75Y avg ≈29.9 | ≈29.9 | · | · | |
| Price / Cash Flow (TTM) | 16.25Y avg ≈28.0 | ≈28.0 | 13.6 | Overvalued | |
| Price / Tangible Book (MRQ) | 9.95Y avg ≈5.7 | ≈5.7 | · | · | |
| PEG Ratio | ≈9.0 | · | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | NBIX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Operating Margin (TTM) | 23.6%5Y avg ≈17.0% | ≈17.0% | 15.8% | In line | |
| EBITDA Margin | 21.6%5Y avg ≈17.0% | ≈17.0% | 15.8% | In line | |
| Pretax Margin (TTM) | 27.9%5Y avg ≈17.2% | ≈17.2% | 16.9% | In line | |
| Net Profit Margin (TTM) | 20.9%5Y avg ≈12.5% | ≈12.5% | 15.1% | In line | |
| ROA (TTM) | 15.3%5Y avg ≈8.4% | ≈8.4% | -0.46% | Top tier | |
| ROE (TTM) | 22.1%5Y avg ≈11.4% | ≈11.4% | 17.4% | In line | |
| ROIC | 12.9%5Y avg ≈10.8% | ≈10.8% | 14.5% | Weak |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | NBIX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio (MRQ) | 1.95Y avg ≈3.2 | ≈3.2 | 3.3 | Low liquidity | |
| Quick Ratio | 1.95Y avg ≈1.8 | ≈1.8 | 2.5 | Low liquidity |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
| Metric | 5Y trend | NBIX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue YoY | 21.4%5Y avg ≈22.5% | ≈22.5% | · | · | |
| Revenue CAGR 3Y | 24.3%5Y avg ≈24.6% | ≈24.6% | · | · | |
| Revenue CAGR 5Y | 22.3% | · | · | · | |
| EPS YoY | 41.9%5Y avg ≈25.0% | ≈25.0% | · | · | |
| Net Income YoY | 40.2%5Y avg ≈26.6% | ≈26.6% | · | · | |
| EPS CAGR 3Y | 44.1%5Y avg ≈27.0% | ≈27.0% | · | · | |
| EPS CAGR 5Y | 2.3% | · | · | · | |
| Net Income CAGR 3Y | 45.8%5Y avg ≈29.0% | ≈29.0% | · | · | |
| Net Income CAGR 5Y | 3.3% | · | · | · |
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | NBIX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Asset Turnover | 0.75Y avg ≈0.7 | ≈0.7 | 0.6 | In line | |
| Inventory Turnover | 0.85Y avg ≈0.8 | ≈0.8 | 1.6 | Weak | |
| Receivables Turnover | 4.95Y avg ≈5.4 | ≈5.4 | 7.0 | Weak | |
| Revenue / Employee | ≈$1.1M | · | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
11.3%
Next Report
Oct 26, 2026
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Jul 28, 2026 | $1.39 | $1.37 | 1.5% |
| March 31, 2026 | $1.91 | $1.20 | 59.5% | |
| Dec. 31, 2025 | $1.91 | $1.20 | 59.5% | |
| Sept. 30, 2025 | $2.04 | $1.62 | 26.1% | |
| June 30, 2025 | $1.06 | $0.99 | 7.0% | |
| March 31, 2025 | $0.08 | $0.56 | -85.6% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.86B | $2.36B | $1.89B | $1.49B | $1.13B | $1.05B | $788M | $451M | $162M | $15M | $20M | $0 | |
| Cost of Revenue | $52M | $34M | $40M | $23M | $14M | $10M | · | $5M | $1M | $0 | $0 | · | |
| R&D Expense | · | · | · | · | · | · | · | $161M | $122M | $94M | $81M | $46M | |
| SG&A Expense | $1.16B | $1.01B | $888M | $753M | $583M | $433M | $354M | $249M | $170M | $68M | $32M | $18M | |
| Operating Expenses | $2.24B | $1.78B | $1.64B | $1.24B | $1.03B | $883M | $716M | $414M | $293M | $162M | $114M | $64M | |
| Operating Income | $619M | $570M | $251M | $249M | $102M | $163M | $72M | $37M | $-131M | $-147M | $-94M | $-64M | |
| Interest Expense | · | · | $5M | $7M | $26M | $33M | $32M | $30M | $20M | $0 | $0 | · | |
| Interest Income | · | · | · | · | · | · | · | · | · | $3M | $2M | $629.0K | |
| Other Non-op | $86M | $-84M | $81M | $-35M | $-1M | $-56M | $-26M | $-15M | $-11M | $6M | $20.0K | $18.0K | |
| Pretax Income | $705M | $486M | $332M | $214M | $101M | $107M | $46M | $22M | $-143M | $-141M | · | · | |
| Income Tax | $227M | $145M | $82M | $59M | $12M | $-301M | $10M | $700.0K | $0 | $0 | $0 | $0 | |
| Net Income | $479M | $341M | $250M | $154M | $90M | $407M | $37M | $21M | $-143M | $-141M | $-89M | $-61M | |
| EPS (Basic) | $4.81 | $3.40 | $2.56 | $1.61 | $0.95 | $4.38 | $0.40 | $0.23 | $-1.62 | $-1.63 | $-1.05 | $-0.81 | |
| EPS (Diluted) | $4.67 | $3.29 | $2.47 | $1.56 | $0.92 | $4.16 | $0.39 | $0.22 | $-1.62 | $-1.63 | $-1.05 | $-0.81 | |
| Shares (Basic) | 99,500,000 | 100,400,000 | 97,700,000 | 95,800,000 | 94,600,000 | 93,100,000 | 91,600,000 | 90,200,000 | 88,089,000 | 86,713,000 | 84,496,000 | 74,577,000 | |
| Shares (Diluted) | 102,500,000 | 103,700,000 | 101,000,000 | 98,900,000 | 97,900,000 | 97,800,000 | 95,700,000 | 95,400,000 | 88,089,000 | 86,713,000 | 84,496,000 | 74,577,000 | |
| EBITDA | $619M | $570M | $251M | $249M | $102M | $163M | $72M | $37M | $-131M | $-147M | · | $-64M |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $713M | $233M | $251M | $263M | $341M | $187M | $112M | $142M | $255M | $83M | $74M | $31M | |
| Short-term Investments | · | · | · | · | $370M | $614M | $558M | $509M | $261M | $224M | $305M | $163M | |
| Receivables | $687M | $479M | $439M | $350M | $186M | $157M | $127M | $57M | $31M | $0 | · | · | |
| Inventory | $69M | $57M | $38M | $35M | $30M | $28M | $17M | $11M | $1M | $0 | · | · | |
| Prepaid Expense | $171M | $48M | · | · | · | · | · | · | · | · | · | · | |
| Other Current Assets | $116M | $64M | $98M | $79M | $46M | $30M | $17M | $19M | $7M | $3M | $5M | $4M | |
| Current Assets | $2.52B | $1.72B | $1.61B | $1.45B | $973M | $1.02B | $831M | $738M | $555M | $310M | $384M | $198M | |
| PP&E (Net) | $90M | $83M | $71M | $59M | $59M | $45M | $42M | $34M | $11M | $6M | $3M | $3M | |
| PP&E (Gross) | $208M | $189M | $154M | $125M | $110M | $86M | $76M | $62M | $38M | $32M | $30M | $31M | |
| Accum. Depreciation | $118M | $106M | $83M | $66M | $52M | $42M | $34M | $28M | $28M | $26M | $27M | $29M | |
| Goodwill | $6M | $6M | $6M | $5M | $0 | · | · | · | · | · | · | · | |
| Intangibles | $5M | $36M | $36M | $37M | $0 | · | · | · | · | · | · | · | |
| Other Non-current Assets | $49M | $52M | $50M | $25M | $4M | $6M | $0 | · | · | · | · | · | |
| Total Assets | $4.63B | $3.72B | $3.25B | $2.37B | $2.07B | $1.73B | $1.31B | $993M | $818M | $365M | $475M | $243M | |
| Accounts Payable | $674M | $462M | $449M | $348M | $226M | $169M | $141M | $86M | $6M | $5M | $3M | $246.0K | |
| Accrued Liabilities | · | · | · | · | · | · | · | · | · | $21M | $19M | $12M | |
| Current Liabilities | $743M | $508M | $655M | $538M | $246M | $186M | $565M | $88M | $54M | $30M | $26M | $16M | |
| Capital Leases | $415M | $455M | $258M | $94M | $105M | $94M | $87M | $0 | · | · | · | · | |
| Deferred Tax | $0 | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $220M | $166M | $106M | $30M | $12M | $10M | $17M | $36M | $0 | $113.0K | $221.0K | $260.0K | |
| Total Liabilities | $1.38B | $1.13B | $1.02B | $661M | $698M | $608M | $669M | $512M | $445M | $50M | $50M | $34M | |
| Common Stock | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $91.0K | $89.0K | $87.0K | $86.0K | $76.0K | |
| Paid-in Capital | · | · | · | · | · | · | · | · | · | · | · | $1.04B | |
| Retained Earnings | $448M | $29M | $-157M | $-407M | $-636M | $-725M | $-1.13B | $-1.18B | $-1.20B | $-1.06B | $-915M | $-826M | |
| AOCI | $13M | $6M | $7M | $-8M | $-2M | $2M | $1M | $-2M | $-2M | $-318.0K | $-977.0K | $-277.0K | |
| Stockholders' Equity | $3.25B | $2.59B | $2.23B | $1.71B | $1.37B | $1.13B | $637M | $481M | $372M | $315M | $424M | $209M | |
| Liabilities + Equity | $4.63B | $3.72B | $3.25B | $2.37B | $2.07B | $1.73B | $1.31B | $993M | $818M | $365M | $475M | $243M | |
| Shares Outstanding | 100,100,000 | 99,400,000 | 98,700,000 | 96,500,000 | 94,900,000 | 93,500,000 | 92,300,000 | 90,797,000 | 88,793,903 | 86,883,300 | 86,262,594 | 76,465,942 |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | $4M | $2M | $1M | $1M | $827.0K | |
| Stock-based Comp | $218M | $196M | $194M | $173M | $134M | $100M | $75M | $58M | $43M | $28M | $28M | $10M | |
| Deferred Tax | $164M | $-123M | $-61M | $22M | $6M | $-311M | $0 | $0 | · | · | · | · | |
| Amort. of Intangibles | $4M | $4M | $4M | $500.0K | $0 | $0 | · | · | · | · | · | · | |
| Operating Cash Flow | $783M | $595M | $390M | $339M | $256M | $228M | $147M | $101M | $-94M | $-106M | $-38M | $-47M | |
| CapEx | $34M | $38M | $28M | $16M | $23M | $11M | $15M | $25M | $7M | $4M | $2M | $2M | |
| Investing Cash Flow | $-264M | $-127M | $-467M | $-177M | $-130M | $4M | $-211M | $-243M | $-251M | $113M | · | · | |
| Stock Issued | $129M | $122M | $65M | $45M | $28M | $29M | $32M | $30M | $14M | $2M | $277M | $139M | |
| Stock Repurchased | $168M | $300M | $0 | $0 | · | · | · | · | · | · | · | · | |
| Net Stock Activity | $-38M | $-178M | $65M | $45M | $28M | $29M | $27M | $30M | $14M | $2M | · | $139M | |
| Financing Cash Flow | $-38M | $-487M | $65M | $-234M | $27M | $-158M | $32M | $30M | $517M | $2M | · | · | |
| Net Change in Cash | $480M | $-18M | $-12M | $-73M | $154M | $75M | $-32M | $-112M | $171M | $9M | $43M | $-14M | |
| Taxes Paid | $81M | · | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $749M | $557M | $362M | $323M | $233M | $218M | $137M | $77M | $-101M | $-110M | · | $-49M | |
| Levered FCF | · | · | $358M | $318M | $210M | $92M | $112M | $47M | · | · | · | · |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 21.6% | 24.2% | 13.3% | 16.7% | 9.0% | 15.6% | 9.2% | 8.2% | -81.3% | -982.5% | · | · | |
| Net Margin | 16.7% | 14.5% | 13.2% | 10.4% | 7.9% | 38.9% | 4.7% | 4.7% | -88.2% | -940.6% | · | · | |
| Pretax Margin | 24.7% | 20.6% | 17.6% | 14.4% | 8.9% | 10.2% | 5.9% | 4.8% | · | · | · | · | |
| EBITDA Margin | 21.6% | 24.2% | 13.3% | 16.7% | 9.0% | 15.6% | 9.2% | 8.2% | -81.3% | -982.5% | · | · | |
| ROA | 11.5% | 9.8% | 8.9% | 7.0% | 4.7% | 26.8% | 3.2% | 2.3% | -24.1% | -33.6% | · | -30.4% | |
| ROE | 16.1% | 12.9% | 11.8% | 9.5% | 6.6% | 42.2% | 6.1% | 4.5% | -41.5% | -38.2% | · | -36.8% | |
| ROIC | 12.9% | 15.5% | 8.5% | 10.5% | 6.6% | 55.2% | 9.0% | 7.4% | · | · | · | · |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.4 | 3.4 | 2.5 | 2.7 | 4.0 | 5.4 | 1.5 | 8.4 | 10.2 | 10.2 | · | 12.7 | |
| Quick Ratio | 1.9 | 1.4 | 1.1 | 1.1 | 3.6 | 5.1 | 1.4 | 2.2 | 10.1 | 10.1 | · | 12.4 | |
| Interest Coverage | · | · | 54.5 | 35.1 | 4.0 | 5.0 | 2.3 | 1.2 | -6.7 | · | · | · |
Efficiency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.7 | 0.7 | 0.7 | 0.7 | 0.6 | 0.7 | 0.7 | 0.5 | 0.3 | 0.0 | · | 0.0 | |
| Inventory Turnover | 0.8 | 0.7 | 1.1 | 0.7 | · | · | · | 0.8 | · | · | · | · | |
| Receivables Turnover | 4.9 | 5.1 | 4.8 | 5.6 | 6.6 | 7.4 | 8.6 | 10.3 | 10.4 | · | · | · |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $32.50 | $26.05 | $22.61 | $17.70 | $14.48 | $12.04 | $6.90 | $5.29 | $4.19 | $3.62 | · | $2.73 | |
| Revenue / Share | $27.91 | $22.71 | $18.68 | $15.05 | $11.58 | $10.69 | $8.23 | $4.73 | $1.83 | $0.17 | · | $0.00 | |
| Cash Flow / Share | $7.64 | $5.74 | $3.86 | $3.43 | $2.62 | $2.34 | $1.59 | $1.06 | $-1.07 | $-1.22 | · | $-0.63 | |
| Cash / Share | $7.12 | $2.34 | $2.54 | $2.72 | $3.59 | $2.00 | $1.22 | $1.56 | $2.87 | $0.96 | · | $0.41 | |
| EPS (TTM) | $4.67 | $3.29 | $2.47 | $1.56 | $0.92 | $4.16 | $0.39 | $0.22 | $-1.62 | $-1.63 | $-1.05 | $-0.81 |
Growth Rates
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 21.4% | 24.8% | 26.8% | 31.3% | 8.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 24.3% | 27.6% | 21.7% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 22.3% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 41.9% | 33.2% | 58.3% | 69.6% | -77.9% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 44.1% | 52.9% | -16.0% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 2.3% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 40.2% | 36.7% | 61.6% | 72.4% | -78.0% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 45.8% | 56.2% | -15.0% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 3.3% | · | · | · | · | · | · | · | · | · | · | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $2.86B | $2.36B | $1.89B | $1.49B | $1.13B | $1.05B | $788M | $451M | $162M | $15M | $20M | $0 | |
| Net Income TTM | $479M | $341M | $250M | $154M | $90M | $407M | $37M | $21M | $-143M | $-141M | $-89M | $-61M | |
| Market Cap | $14.20B | $13.57B | $13.00B | $11.53B | $8.08B | $8.96B | $9.92B | $6.48B | $6.89B | $3.36B | · | $1.71B | |
| P/E | 30.4 | 41.5 | 53.3 | 76.6 | 92.6 | 23.0 | 275.6 | 324.6 | -47.9 | -23.7 | -53.9 | -27.6 | |
| P/S | 5.0 | 5.8 | 6.9 | 7.7 | 7.1 | 8.6 | 12.6 | 14.4 | 42.6 | 224.2 | · | · | |
| P/B | 4.4 | 5.2 | 5.8 | 6.7 | 5.9 | 8.0 | 15.6 | 13.5 | 18.5 | 10.7 | · | 8.2 | |
| P / Tangible Book | 4.4 | 5.3 | 5.9 | 6.9 | 5.9 | 8.0 | · | · | · | · | · | · | |
| P / Cash Flow | 18.1 | 22.8 | 33.4 | 34.0 | 31.5 | 39.2 | 65.2 | 64.0 | -73.0 | -31.7 | · | -36.2 | |
| P / FCF | 19.0 | 24.4 | 36.0 | 35.7 | 34.7 | 41.2 | 72.2 | 84.7 | -68.0 | -30.5 | · | -35.0 | |
| Earnings Yield | 3.3% | 2.4% | 1.9% | 1.3% | 1.1% | 4.3% | 0.36% | 0.31% | -2.1% | -4.2% | -1.9% | -3.6% |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $959M | $814M | $806M | $795M | $688M | $573M | $628M | $622M | $590M | $515M | $515M | $499M | $453M | $420M | $412M | $388M | |
| Cost of Revenue | · | $14M | $18M | $14M | $11M | $9M | $9M | $8M | $9M | $8M | $8M | $11M | $12M | $8M | $8M | $6M | |
| SG&A Expense | $440M | $318M | $302M | $292M | $286M | $276M | $288M | $234M | $242M | $243M | $219M | $204M | $222M | $243M | $183M | $186M | |
| Operating Expenses | $808M | $621M | $595M | $556M | $542M | $549M | $486M | $438M | $445M | $416M | $365M | $358M | $379M | $535M | $309M | $300M | |
| Operating Income | $152M | $193M | $211M | $239M | $146M | $24M | $142M | $184M | $145M | $99M | $150M | $141M | $74M | $-114M | $103M | $88M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $1M | · | $1M | $1M | $1M | · | $1M | |
| Other Non-op | $11M | $53M | $28M | $53M | $14M | $-9M | $21M | $6M | $-47M | $-65M | $48M | $-26M | $48M | $11M | $14M | $10M | |
| Pretax Income | $162M | $247M | $239M | $292M | $160M | $15M | $163M | $190M | $99M | $34M | $198M | $116M | $122M | $-103M | $118M | $98M | |
| Income Tax | $18M | $49M | $86M | $82M | $52M | $7M | $60M | $60M | $34M | $-9M | $50M | $32M | $26M | $-27M | $29M | $29M | |
| Net Income | $144M | $198M | $154M | $210M | $108M | $8M | $103M | $130M | $65M | $43M | $148M | $83M | $96M | $-77M | $89M | $68M | |
| EPS (Basic) | $1.43 | $1.97 | $1.53 | $2.11 | $1.09 | $0.08 | $1.05 | $1.28 | $0.64 | $0.43 | $1.52 | $0.85 | $0.98 | $-0.79 | $0.92 | $0.72 | |
| EPS (Diluted) | $1.39 | $1.91 | $1.49 | $2.04 | $1.06 | $0.08 | $1.00 | $1.24 | $0.63 | $0.42 | $1.49 | $0.82 | $0.95 | $-0.79 | $0.91 | $0.69 | |
| Shares (Basic) | 101,000,000 | 100,500,000 | · | 99,400,000 | 99,000,000 | 99,700,000 | · | 101,100,000 | 100,800,000 | 99,800,000 | · | 97,900,000 | 97,600,000 | 97,100,000 | · | 95,800,000 | |
| Shares (Diluted) | 104,200,000 | 103,400,000 | · | 102,500,000 | 101,000,000 | 102,500,000 | · | 104,300,000 | 103,900,000 | 103,600,000 | · | 101,100,000 | 100,200,000 | 97,100,000 | · | 99,000,000 | |
| EBITDA | $152M | $193M | · | $239M | $146M | $24M | · | $184M | $145M | $99M | · | $141M | $74M | $-114M | · | $88M |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $332M | $266M | $713M | $340M | $264M | $194M | $233M | $349M | $140M | $396M | · | $294M | $160M | $104M | · | $212M | |
| Receivables | $887M | $768M | $687M | $728M | $596M | $516M | $479M | $481M | $468M | $451M | · | $418M | $388M | $392M | · | $301M | |
| Inventory | $104M | $64M | $69M | $69M | $57M | $59M | $57M | $46M | $42M | $37M | · | $29M | $32M | $33M | · | $37M | |
| Prepaid Expense | $217M | $225M | $171M | $178M | · | · | $48M | · | · | · | · | · | · | · | · | · | |
| Other Current Assets | $39M | $62M | $116M | $68M | $121M | $119M | $64M | $122M | $120M | $100M | · | $108M | $101M | $113M | · | $68M | |
| Current Assets | $1.64B | $2.44B | $2.52B | $2.16B | $1.75B | $1.64B | $1.72B | $1.88B | $1.67B | $1.80B | · | $1.65B | $1.50B | $1.43B | · | $1.21B | |
| PP&E (Net) | $90M | $91M | $90M | $97M | $92M | $87M | $83M | $80M | $80M | $75M | · | $69M | $66M | $63M | · | $61M | |
| PP&E (Gross) | · | · | $208M | · | · | · | $189M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $118M | · | · | · | $106M | · | · | · | · | · | · | · | · | · | |
| Goodwill | $501M | · | · | · | · | · | · | $6M | $6M | $6M | · | $6M | $6M | $6M | $5M | · | |
| Intangibles | $2.23B | · | · | $36M | $37M | $36M | · | $34M | $34M | $34M | · | $35M | $37M | $37M | · | · | |
| Other Non-current Assets | $59M | $74M | $60M | $20M | $22M | $15M | $52M | $62M | $58M | $51M | · | $43M | $36M | $25M | · | $10M | |
| Total Assets | $5.36B | $4.91B | $4.63B | $4.27B | $3.89B | $3.69B | $3.72B | $3.54B | $3.31B | $3.47B | · | $2.85B | $2.61B | $2.36B | · | $2.14B | |
| Accounts Payable | $808M | $773M | $674M | $584M | $490M | $475M | $462M | $393M | $358M | $417M | · | $503M | $392M | $356M | · | $298M | |
| Current Liabilities | $874M | $832M | $743M | $638M | $546M | $523M | $508M | $430M | $398M | $713M | · | $692M | $582M | $374M | · | $485M | |
| Capital Leases | $402M | $406M | $415M | $428M | $439M | $448M | $455M | $251M | $256M | $253M | · | $86M | $89M | $90M | · | $97M | |
| Deferred Tax | $92M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $298M | $261M | $220M | $196M | $210M | $182M | $166M | $135M | $141M | $120M | · | $69M | $88M | $41M | · | $17M | |
| Total Liabilities | $1.67B | $1.50B | $1.38B | $1.26B | $1.20B | $1.15B | $1.13B | $816M | $796M | $1.09B | · | $846M | $760M | $675M | · | $599M | |
| Common Stock | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | · | $100.0K | $100.0K | $100.0K | · | $100.0K | |
| Retained Earnings | $724M | $590M | $448M | $294M | $84M | $-5M | $29M | $81M | $-49M | $-114M | · | $-305M | $-388M | $-483M | · | $-496M | |
| AOCI | $5M | $400.0K | $13M | $13M | $12M | $9M | $6M | $14M | $2M | $3M | · | $-2M | $-1M | $-3M | · | $-14M | |
| Stockholders' Equity | $3.69B | $3.41B | $3.25B | $3.00B | $2.69B | $2.54B | $2.59B | $2.72B | $2.51B | $2.39B | $2.23B | $2.00B | $1.85B | $1.68B | $1.71B | $1.54B | |
| Liabilities + Equity | $5.36B | $4.91B | $4.63B | $4.27B | $3.89B | $3.69B | $3.72B | $3.54B | $3.31B | $3.47B | · | $2.85B | $2.61B | $2.36B | · | $2.14B | |
| Shares Outstanding | 101,600,000 | 100,600,000 | 100,100,000 | 99,700,000 | 99,000,000 | 99,000,000 | 99,400,000 | 101,200,000 | 100,900,000 | 100,600,000 | · | 98,200,000 | 97,600,000 | 97,500,000 | · | 96,100,000 |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $65M | $57M | $59M | $54M | $53M | $53M | $66M | $42M | $43M | $44M | $38M | $48M | $68M | $40M | $44M | $43M | |
| Amort. of Intangibles | $16M | $100.0K | $1M | $1M | $1M | $1M | $900.0K | $900.0K | $900.0K | $900.0K | $800.0K | $900.0K | $900.0K | $900.0K | $500.0K | $0 | |
| Operating Cash Flow | $136M | $146M | $388M | $228M | $102M | $65M | $242M | $158M | $65M | $130M | $124M | $212M | $180M | $-125M | $143M | $99M | |
| CapEx | $8M | $9M | $-2M | $13M | $12M | $11M | $7M | $8M | $12M | $11M | $5M | $8M | $7M | $8M | $2M | $-2M | |
| Investing Cash Flow | $-135M | $-506M | $-53M | $-197M | $-29M | $14M | $-68M | $25M | $-28M | $-55M | $-202M | $-97M | $-126M | $-42M | $-116M | $-61M | |
| Stock Issued | $85M | $24M | $37M | $46M | $14M | $32M | $10M | $26M | $16M | $70M | $35M | $19M | $3M | $8M | $25M | $11M | |
| Stock Repurchased | $12M | $54M | $0 | $0 | $18M | $150M | $300M | $0 | $0 | $0 | · | · | · | · | · | · | |
| Net Stock Activity | · | $-30M | · | · | · | $-118M | · | · | · | $70M | · | · | · | $8M | · | · | |
| Financing Cash Flow | $63M | $-86M | $37M | $46M | $-3M | $-118M | $-290M | $26M | $-293M | $70M | $35M | $19M | $3M | $8M | $25M | $11M | |
| Net Change in Cash | $64M | $-446M | $373M | $76M | $70M | $-39M | $-116M | $209M | $-257M | $145M | $-43M | $134M | $57M | $-159M | $51M | $49M | |
| Free Cash Flow | · | $137M | · | · | · | $54M | · | · | · | $119M | · | · | · | $-134M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $118M | · | · | · | $-135M | · | · |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 15.8% | 23.7% | · | 30.1% | 21.2% | 4.1% | · | 29.5% | 24.6% | 19.3% | · | 28.3% | 16.3% | -27.2% | · | 22.6% | |
| Net Margin | 15.1% | 24.3% | · | 26.4% | 15.6% | 1.4% | · | 20.9% | 11.0% | 8.4% | · | 16.7% | 21.1% | -18.2% | · | 17.7% | |
| Pretax Margin | 16.9% | 30.3% | · | 36.7% | 23.2% | 2.6% | · | 30.6% | 16.7% | 6.7% | · | 23.2% | 26.9% | -24.6% | · | 25.2% | |
| EBITDA Margin | 15.8% | 23.7% | · | 30.1% | 21.2% | 4.1% | · | 29.5% | 24.6% | 19.3% | · | 28.3% | 16.3% | -27.2% | · | 22.6% | |
| ROA | 3.1% | 4.6% | · | 5.4% | 3.0% | 0.22% | · | 4.1% | 2.2% | 1.5% | · | 3.3% | 4.1% | -3.4% | · | 3.3% | |
| ROE | 4.5% | 6.7% | · | 7.3% | 4.1% | 0.32% | · | 5.5% | 3.0% | 2.1% | · | 4.7% | 5.8% | -5.0% | · | 4.7% | |
| ROIC | 3.6% | 4.5% | · | 5.7% | 3.6% | 0.50% | · | 4.6% | 3.8% | 5.2% | · | 5.1% | 3.1% | -5.0% | · | 4.0% |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.9 | 2.9 | · | 3.4 | 3.2 | 3.1 | · | 4.4 | 4.2 | 2.5 | · | 2.4 | 2.6 | 3.8 | · | 2.5 | |
| Quick Ratio | 1.4 | 1.2 | · | 1.7 | 1.6 | 1.4 | · | 1.9 | 1.5 | 1.2 | · | 1.0 | 0.9 | 1.3 | · | 1.1 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | 90.3 | · | 128.4 | 56.6 | -103.8 | · | 73.2 |
Efficiency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | |
| Inventory Turnover | · | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.3 | 0.4 | 0.3 | · | 0.2 | |
| Receivables Turnover | 1.3 | 1.3 | · | 1.3 | 1.3 | 1.2 | · | 1.4 | 1.4 | 1.2 | · | 1.4 | 1.4 | 1.3 | · | 1.7 |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $36.35 | $33.87 | · | $30.13 | $27.22 | $25.61 | · | $26.87 | $24.87 | $23.72 | · | $20.39 | $18.99 | $17.28 | · | $16.07 | |
| Revenue / Share | $9.20 | $7.88 | · | $7.76 | $6.81 | $5.59 | · | $5.96 | $5.68 | $4.97 | · | $4.93 | $4.52 | $4.33 | · | $3.92 | |
| Cash Flow / Share | · | $1.41 | · | · | · | $0.63 | · | · | · | $1.26 | · | · | · | $-1.29 | · | · | |
| Cash / Share | $3.27 | $2.65 | · | $3.41 | $2.67 | $1.96 | · | $3.45 | $1.38 | $3.94 | · | $2.99 | $1.64 | $1.06 | · | $2.21 | |
| EPS (TTM) | $6.83 | $6.50 | · | $4.18 | $3.38 | $2.95 | · | $3.78 | $3.36 | $3.68 | · | $1.89 | $1.76 | $0.63 | · | $0.58 |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $3.37B | $3.10B | · | $2.68B | $2.51B | $2.41B | · | $2.24B | $2.12B | $1.98B | · | $1.78B | $1.67B | $1.60B | · | $1.39B | |
| Net Income TTM | $706M | $669M | · | $428M | $348M | $306M | · | $386M | $339M | $370M | · | $191M | $176M | $64M | · | $58M | |
| Market Cap | $17.12B | $13.25B | · | $14.00B | $12.44B | $10.95B | · | $11.66B | $13.89B | $13.87B | · | $11.05B | $9.20B | $9.87B | · | $10.21B | |
| P/E | 24.7 | 20.3 | · | 33.6 | 37.2 | 37.5 | · | 30.5 | 41.0 | 37.5 | · | 59.5 | 53.6 | 160.7 | · | 183.1 | |
| P/S | 5.1 | 4.3 | · | 5.2 | 5.0 | 4.5 | · | 5.2 | 6.6 | 7.0 | · | 6.2 | 5.5 | 6.2 | · | 7.3 | |
| P/B | 4.6 | 3.9 | · | 4.7 | 4.6 | 4.3 | · | 4.3 | 5.5 | 5.8 | · | 5.5 | 5.0 | 5.9 | · | 6.6 | |
| P / Tangible Book | 17.7 | 3.9 | · | 4.7 | 4.7 | 4.4 | · | 4.4 | 5.6 | 5.9 | · | 5.6 | 5.1 | 6.0 | · | 6.6 | |
| P / Cash Flow | · | 90.9 | · | · | · | 169.0 | · | · | · | 106.5 | · | · | · | -78.8 | · | · | |
| Earnings Yield | 4.0% | 4.9% | · | 3.0% | 2.7% | 2.7% | · | 3.3% | 2.4% | 2.7% | · | 1.7% | 1.9% | 0.62% | · | 0.55% |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenue | $2.86B | $2.36B | $1.89B | $1.49B | $1.13B |
| Operating Margin % | 21.6% | 24.2% | 13.3% | 16.7% | 9.0% |
| Net Income | $479M | $341M | $250M | $154M | $90M |
| Diluted EPS | $4.67 | $3.29 | $2.47 | $1.56 | $0.92 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Current Ratio | 3.4 | 3.4 | 2.5 | 2.7 | 4.0 |
| Quick Ratio | 1.9 | 1.4 | 1.1 | 1.1 | 3.6 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Free Cash Flow | $749M | $557M | $362M | $323M | $233M |
Institutional owners (13F) 825 filers · $18.1B total · As of Sept. 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
825
Value held
$18.1B
New positions
148
Exited positions
62
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 148 (+50 vs prior Q) | 62 (-36 vs prior Q) | 317 (+16 vs prior Q) | 226 (+12 vs prior Q) | +587K |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| BlackRock, Inc. | $2,310,885,707 | 13,711,607 | 12.75% | Shares |
| VANGUARD GROUP INC | $1,375,793,692 | 9,700,301 | 7.59% | Shares |
| JPMORGAN CHASE & CO | $1,088,569,109 | 6,398,674 | 6.01% | Shares |
| Dodge & Cox | $941,218,594 | 5,584,707 | 5.19% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $838,307,078 | 4,974,083 | 4.63% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $766,048,708 | 4,545,339 | 4.23% | Shares |
| STATE STREET CORP | $739,126,759 | 4,385,598 | 4.08% | Shares |
| AQR CAPITAL MANAGEMENT LLC | $643,472,716 | 3,818,037 | 3.55% | Shares |
| RENAISSANCE TECHNOLOGIES LLC | $393,680,402 | 2,335,897 | 2.17% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $359,607,676 | 2,138,777 | 1.98% | Shares |
| TWO SIGMA INVESTMENTS, LP | $349,922,479 | 2,076,260 | 1.93% | Shares |
| Vestal Point Capital, LP | $316,845,800 | 1,880,000 | 1.75% | Shares |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $251,858,951 | 1,494,259 | 1.39% | Shares |
| MORGAN STANLEY | $222,231,858 | 1,318,607 | 1.23% | Shares |
| RTW INVESTMENTS, LP | $213,689,740 | 1,267,925 | 1.18% | Shares |
| NORTHERN TRUST CORP | $212,306,405 | 1,259,717 | 1.17% | Shares |
| Invesco Ltd. | $181,565,621 | 1,077,317 | 1.00% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $164,200,136 | 974,279 | 0.91% | Shares |
| NORGES BANK | $164,132,866 | 973,880 | 0.91% | Shares |
| FIRST TRUST ADVISORS LP | $155,578,851 | 923,125 | 0.86% | Shares |
| DIMENSIONAL FUND ADVISORS LP | $123,525,529 | 732,877 | 0.68% | Shares |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $122,375,286 | 726,112 | 0.68% | Shares |
| TWO SIGMA ADVISERS, LP | $119,504,823 | 842,592 | 0.66% | Shares |
| Bank of New York Mellon Corp | $117,826,993 | 699,125 | 0.65% | Shares |
| Swedbank AB | $109,730,107 | 651,082 | 0.61% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $109,170,737 | 647,763 | 0.60% | Shares |
| IEQ CAPITAL, LLC | $107,913,614 | 640,304 | 0.60% | Shares |
| GOLDMAN SACHS GROUP INC | $106,495,877 | 631,892 | 0.59% | Shares |
| BANK OF AMERICA CORP /DE/ | $104,382,489 | 619,352 | 0.58% | Shares |
| VICTORY CAPITAL MANAGEMENT INC | $104,238,729 | 618,499 | 0.58% | Shares |
| Man Group plc | $101,292,738 | 601,019 | 0.56% | Shares |
| ROYAL BANK OF CANADA | $98,337,000 | 583,476 | 0.54% | Shares |
| RAYMOND JAMES FINANCIAL INC | $97,778,953 | 580,170 | 0.54% | Shares |
| FRANKLIN RESOURCES INC | $93,211,316 | 553,068 | 0.51% | Shares |
| UBS Group AG | $92,009,492 | 545,937 | 0.51% | Shares |
| Caisse de depot et placement du Quebec | $91,002,327 | 539,961 | 0.50% | Shares |
| ARMISTICE CAPITAL, LLC | $90,307,457 | 535,838 | 0.50% | Shares |
| AMERIPRISE FINANCIAL INC | $84,660,571 | 502,267 | 0.47% | Shares |
| PRIMECAP MANAGEMENT CO/CA/ | $82,807,988 | 491,340 | 0.46% | Shares |
| Hood River Capital Management LLC | $79,082,184 | 469,233 | 0.44% | Shares |
| Nuveen, LLC | $77,408,341 | 459,301 | 0.43% | Shares |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $75,318,261 | 571,719 | 0.42% | Shares |
| Pictet Asset Management Holding SA | $72,751,030 | 430,635 | 0.40% | Shares |
| Rockefeller Capital Management L.P. | $62,955,982 | 373,548 | 0.35% | Shares |
| Fiera Capital Corp | $62,895,914 | 373,192 | 0.35% | Shares |
| Gotham Asset Management, LLC | $62,622,213 | 371,568 | 0.35% | Shares |
| JANUS HENDERSON GROUP PLC | $61,515,240 | 466,977 | 0.34% | Shares |
| ALLIANCEBERNSTEIN L.P. | $60,767,710 | 461,270 | 0.34% | Shares |
| Vinva Investment Management Ltd | $58,838,530 | 346,109 | 0.32% | Shares |
| AustralianSuper Pty Ltd | $58,817,535 | 348,993 | 0.32% | Shares |
Activists & 5%+ owners 1 position
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Neurocrine Biosciences, Inc. ×3 filings | Feb. 24, 2023 | · | Initial filing | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 41 insiders · 22 officers · 15 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Kyle Gano | Chief Executive Officer | Sept. 11, 2026 F | 154,728 | 0 | 3 | $-4,872,890 |
| Matt Abernethy | Chief Financial Officer | Sept. 14, 2026 S | 42,808 | 0 | 1 | $-363,289 |
| Timothy Coughlin | Chief Financial Officer | Feb. 6, 2017 S | 137,961 | 0 | 0 | $0 |
| David-Alexandre C Gros | President & COO | Feb. 6, 2017 A | · | 0 | 0 | $0 |
| David W. Boyer | Chief Corp. Affairs Officer | Sept. 14, 2026 S | 8,722 | 0 | 2 | $-739,070 |
| Ingrid Delaet | Chief Regulatory Officer | Sept. 11, 2026 F | 18,289 | 0 | 5 | $-3,747,962 |
| Jude Onyia | Chief Scientific Officer | Sept. 11, 2026 F | 22,647 | 0 | 2 | $-3,473,580 |
| Sanjay Chandru Keswani | Chief Medical Officer | Sept. 11, 2026 F | 3,281 | 0 | 0 | $0 |
| Julie Cooke | Chief Human Resources Officer | Sept. 11, 2026 F | 24,025 | 0 | 5 | $-5,770,377 |
| Eric Benevich | Chief Commercial Officer | Sept. 11, 2026 F | 67,297 | 0 | 2 | $-1,238,918 |
| Darin Lippoldt | Chief Legal Officer | Sept. 11, 2026 F | 56,793 | 0 | 5 | $-4,196,071 |
| Eiry Roberts | Chief Medical Officer | Feb. 13, 2025 M | 35,640 | 0 | 0 | $0 |
| Malcolm Lloyd-Smith | Chief Integration Officer | Feb. 8, 2023 S | 42,337 | 0 | 0 | $0 |
| Dimitri E. Grigoriadis | Chief Research Officer | Jan. 31, 2022 A | 82,273 | 0 | 0 | $0 |
| Haig P. Bozigian | Chief Development Officer | Feb. 8, 2021 A | 157,651 | 0 | 0 | $0 |
| Christopher Flint Obrien | Former Chief Medical Officer | Feb. 5, 2018 A | 55,946 | 0 | 0 | $0 |
| VALEUR JENSEN MARGARET E | EVP and General Counsel | Aug. 31, 2011 A | 118,256 | 0 | 0 | $0 |
| Richard J Ranieri | Sr. VP, Human Resources | Feb. 27, 2008 A | 9,667 | 0 | 0 | $0 |
| Wendall Wierenga | EVP, Research & Development | Jan. 19, 2006 A | 5,023 | 0 | 0 | $0 |
| Henry Pan | Executive VP and CMO | June 3, 2005 A | 11,216 | 0 | 0 | $0 |
| Robert J Little | SVP, Commercial Operations | Feb. 18, 2005 A | · | 0 | 0 | $0 |
| SAUNDERS JOHN | Vice President Research (Chem) | Dec. 18, 2003 S | 7,966 | 0 | 0 | $0 |
| Kevin Charles Gorman | Director | Sept. 11, 2026 F | 517,797 | 0 | 1 | $-37,824,431 |
| SHERWIN STEPHEN A | Director | Sept. 2, 2026 G | 14,860 | 0 | 5 | $-4,132,990 |
| Leslie V Norwalk | Director | July 29, 2026 M | 2,430 | 0 | 5 | $-1,973,882 |
| Johanna Mercier | Director | May 27, 2026 A | 6,853 | 0 | 0 | $0 |
| William H Rastetter | Director | May 27, 2026 A | 43,678 | 0 | 1 | $-2,732,760 |
| Christine A Poon | Director | May 27, 2026 A | 4,753 | 0 | 0 | $0 |
| POPS RICHARD F | Director | May 27, 2026 A | 37,798 | 0 | 1 | $-2,364,750 |
| LYONS GARY A | Director | May 27, 2026 A | 122,141 | 0 | 1 | $-2,289,150 |
| MORROW GEORGE J | Director | May 27, 2026 A | 10,386 | 0 | 1 | $-2,150,550 |
| Alfred Sandrock | Director | May 22, 2019 A | · | 0 | 0 | $0 |
| Corinne H Nevinny | Director | May 24, 2018 A | 43,283 | 0 | 0 | $0 |
| Thomas W Mitchell | Director | May 28, 2015 A | 1,000 | 0 | 0 | $0 |
| VALE WYLIE W | Director | May 25, 2011 A | 231,372 | 0 | 0 | $0 |
| Adrian Adams | Director | June 30, 2006 A | · | 0 | 0 | $0 |
| Shalini Sharp | · | May 27, 2026 A | 4,088 | 0 | 0 | $0 |
| MOLLICA JOSEPH A | · | May 22, 2017 A | 56,042 | 0 | 0 | $0 |
| HAWRAN PAUL W | · | Sept. 18, 2006 J | 132,000 | 0 | 0 | $0 |
| Lawrence Steinman | · | March 2, 2005 S | 15,500 | 0 | 0 | $0 |
| CONLON PAUL J | · | Dec. 16, 2003 S | 57,335 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 104 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| IBRN · iShares Trust | 3.75% | 1,793 SH | Sept. 11, 2026 | Daily |
| PBE · Invesco Exchange-Traded Fund Trust | 2.60% | 76,511 SH | Oct. 2, 2026 | Daily |
| MCOW · Pacer Funds Trust | 2.57% | 164 NS | July 31, 2026 | N-PORT |
| BUL · Pacer Funds Trust | 2.15% | 16,896 NS | July 31, 2026 | N-PORT |
| CVSM · Elevation Series Trust | 2.04% | 11,525 NS | July 31, 2026 | N-PORT |
| JMID · Janus Detroit Street Trust | 1.93% | 2,742 NS | July 31, 2026 | N-PORT |
| POWA · Invesco Exchange-Traded Self-Indexe… | 1.92% | 22,570 SH | Oct. 2, 2026 | Daily |
| FGSI · First Trust Exchange-Traded Fund IV | 1.90% | 236 NS | July 31, 2026 | N-PORT |
| ABOT · Abacus FCF ETF Trust | 1.90% | 460 NS | July 31, 2026 | N-PORT |
| XMHQ · Invesco Exchange-Traded Fund Trust | 1.74% | 667,222 SH | Oct. 2, 2026 | Daily |
| FXH · First Trust Exchange-Traded AlphaDE… | 1.67% | 105,135 NS | July 31, 2026 | N-PORT |
| GRPM · Invesco Exchange-Traded Fund Trust | 1.61% | 56,862 SH | Oct. 2, 2026 | Daily |
| BBP · ETFis Series Trust I | 1.44% | 8,494 NS | July 31, 2026 | N-PORT |
| CSMD · Professionally Managed Portfolios | 1.18% | 32,094 NS | July 31, 2026 | N-PORT |
| IBB · iShares Trust | 1.14% | 755,021 SH | Sept. 11, 2026 | Daily |
| AGRW · ALLSPRING EXCHANGE-TRADED FUNDS TRU… | 1.11% | 7,516 NS | July 31, 2026 | N-PORT |
| JSMD · Janus Detroit Street Trust | 1.05% | 66,455 NS | July 31, 2026 | N-PORT |
| RFG · Invesco Exchange-Traded Fund Trust | 1.04% | 24,859 SH | Oct. 2, 2026 | Daily |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0.96% | 7,190 SH | Oct. 2, 2026 | Daily |
| IVOG · VANGUARD ADMIRAL FUNDS | 0.89% | 99,214 SH | Aug. 19, 2026 | Daily |
| COWG · Pacer Funds Trust | 0.78% | 103,520 NS | July 31, 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 0.73% | 399 NS | July 31, 2026 | N-PORT |
| LSEQ · Harbor ETF Trust | 0.72% | 661 NS | July 31, 2026 | N-PORT |
| QQQJ · Invesco Exchange-Traded Fund Trust … | 0.72% | 59,939 SH | Oct. 2, 2026 | Daily |
| LABU · Direxion Shares ETF Trust | 0.71% | 20,978 NS | July 31, 2026 | N-PORT |
| IQSM · New York Life Investments ETF Trust | 0.63% | 12,528 NS | July 31, 2026 | N-PORT |
| FNY · First Trust Exchange-Traded AlphaDE… | 0.63% | 21,784 NS | July 31, 2026 | N-PORT |
| QLV · FlexShares Trust | 0.56% | 5,460 NS | July 31, 2026 | N-PORT |
| ISCG · iShares Trust | 0.52% | 31,868 SH | Sept. 11, 2026 | Daily |
| PTMC · Pacer Funds Trust | 0.47% | 11,072 NS | July 31, 2026 | N-PORT |
| USMV · iShares Trust | 0.46% | 697,795 SH | Sept. 11, 2026 | Daily |
| VBK · VANGUARD INDEX FUNDS | 0.46% | 1,331,820 SH | Aug. 19, 2026 | Daily |
| IVOO · VANGUARD ADMIRAL FUNDS | 0.46% | 162,408 SH | Aug. 19, 2026 | Daily |
| QVMM · Invesco Exchange-Traded Fund Trust … | 0.45% | 13,252 SH | Oct. 2, 2026 | Daily |
| SMDX · Tidal Trust III | 0.43% | 3,374 NS | July 31, 2026 | N-PORT |
| BKMC · BNY Mellon ETF Trust | 0.42% | 16,429 NS | July 31, 2026 | N-PORT |
| IWP · iShares Trust | 0.39% | 480,949 SH | Sept. 11, 2026 | Daily |
| SDG · iShares Trust | 0.38% | 4,071 SH | Sept. 11, 2026 | Daily |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0.36% | 44,021 NS | July 31, 2026 | N-PORT |
| MIDU · Direxion Shares ETF Trust | 0.36% | 1,476 NS | July 31, 2026 | N-PORT |
| FSMD · FIDELITY COVINGTON TRUST | 0.31% | 46,187 NS | July 31, 2026 | N-PORT |
| FNX · First Trust Exchange-Traded AlphaDE… | 0.30% | 24,447 NS | July 31, 2026 | N-PORT |
| JPME · J.P. Morgan Exchange-Traded Fund Tr… | 0.29% | 8,053 NS | July 31, 2026 | N-PORT |
| COWZ · Pacer Funds Trust | 0.25% | 283,150 NS | July 31, 2026 | N-PORT |
| IYH · iShares Trust | 0.25% | 57,843 SH | Sept. 11, 2026 | Daily |
| VHT · VANGUARD WORLD FUND | 0.24% | 286,599 SH | Aug. 19, 2026 | Daily |
| FHLC · FIDELITY COVINGTON TRUST | 0.23% | 45,259 NS | July 31, 2026 | N-PORT |
| SMMD · iShares Trust | 0.21% | 52,744 SH | Sept. 11, 2026 | Daily |
| EUSA · iShares, Inc. | 0.20% | 25,089 SH | Sept. 11, 2026 | Daily |
| VB · VANGUARD INDEX FUNDS | 0.20% | 2,306,077 SH | Aug. 19, 2026 | Daily |
| PWS · Pacer Funds Trust | 0.20% | 287 NS | July 31, 2026 | N-PORT |
| SIZE · iShares Trust | 0.20% | 5,417 SH | Sept. 11, 2026 | Daily |
| VXF · VANGUARD INDEX FUNDS | 0.19% | 1,153,763 SH | Aug. 19, 2026 | Daily |
| FAD · First Trust Exchange-Traded AlphaDE… | 0.19% | 6,541 NS | July 31, 2026 | N-PORT |
| ACWV · iShares, Inc. | 0.18% | 37,854 SH | Sept. 11, 2026 | Daily |
| RWK · Invesco Exchange-Traded Fund Trust … | 0.13% | 11,381 SH | Oct. 2, 2026 | Daily |
| IWR · iShares Trust | 0.11% | 405,396 SH | Sept. 11, 2026 | Daily |
| FHEQ · Fidelity Greenwood Street Trust | 0.11% | 6,157 NS | July 31, 2026 | N-PORT |
| ESUM · Strategy Shares | 0.10% | 1,133 NS | July 31, 2026 | N-PORT |
| HEQQ · J.P. Morgan Exchange-Traded Fund Tr… | 0.10% | 177 NS | July 31, 2026 | N-PORT |
| LRND · New York Life Investments ETF Trust | 0.10% | 2,270 NS | July 31, 2026 | N-PORT |
| HELO · J.P. Morgan Exchange-Traded Fund Tr… | 0.09% | 23,838 NS | July 31, 2026 | N-PORT |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0.09% | 4,828 SH | Oct. 2, 2026 | Daily |
| DFUV · Dimensional ETF Trust | 0.08% | 70,759 NS | July 31, 2026 | N-PORT |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0.07% | 23,598 SH | Oct. 2, 2026 | Daily |
| DYNF · BlackRock ETF Trust | 0.07% | 177,312 SH | Sept. 11, 2026 | Daily |
| USXF · iShares Trust | 0.06% | 5,665 SH | Sept. 11, 2026 | Daily |
| ESMV · iShares Trust | 0.05% | 26 SH | Sept. 11, 2026 | Daily |
| GARP · iShares Trust | 0.05% | 9,869 SH | Sept. 11, 2026 | Daily |
| DFAC · Dimensional ETF Trust | 0.05% | 141,631 NS | July 31, 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0.05% | 1,484 NS | July 31, 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0.04% | 8,569 NS | July 31, 2026 | N-PORT |
| IUSG · iShares Trust | 0.04% | 89,338 SH | Sept. 11, 2026 | Daily |
| IWF · iShares Trust | 0.04% | 320,069 SH | Sept. 11, 2026 | Daily |
| VONG · VANGUARD SCOTTSDALE FUNDS | 0.04% | 134,662 SH | Aug. 19, 2026 | Daily |
| ESGV · VANGUARD WORLD FUND | 0.03% | 22,375 SH | Aug. 19, 2026 | Daily |
| TILT · FlexShares Trust | 0.03% | 3,888 NS | July 31, 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0.03% | 20,775 NS | July 31, 2026 | N-PORT |
| RECS · Columbia ETF Trust I | 0.02% | 8,549 NS | July 31, 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0.02% | 28,885 NS | July 31, 2026 | N-PORT |
| IYY · iShares Trust | 0.02% | 4,355 SH | Sept. 11, 2026 | Daily |
| IWB · iShares Trust | 0.02% | 68,459 SH | Sept. 11, 2026 | Daily |
| ITOT · iShares Trust | 0.02% | 131,068 SH | Sept. 11, 2026 | Daily |
| IWS · iShares Trust | 0.02% | 20,508 SH | Sept. 11, 2026 | Daily |
| IWV · iShares Trust | 0.02% | 27,012 SH | Sept. 11, 2026 | Daily |
| PBUS · Invesco Exchange-Traded Fund Trust … | 0.02% | 16,531 SH | Oct. 2, 2026 | Daily |
| VTI · VANGUARD INDEX FUNDS | 0.02% | 3,193,839 SH | Aug. 19, 2026 | Daily |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0.02% | 16,227 SH | Aug. 19, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.02% | 8,342 SH | Aug. 19, 2026 | Daily |
| PRF · Invesco Exchange-Traded Fund Trust | 0.02% | 11,591 SH | Oct. 2, 2026 | Daily |
| TOK · iShares Trust | 0.02% | 249 SH | Sept. 11, 2026 | Daily |
| URTH · iShares, Inc. | 0.02% | 8,440 SH | Sept. 11, 2026 | Daily |
| ACWI · iShares Trust | 0.01% | 30,548 SH | Sept. 11, 2026 | Daily |
| DFLV · Dimensional ETF Trust | 0.01% | 4,926 NS | July 31, 2026 | N-PORT |
| DFVX · Dimensional ETF Trust | 0.01% | 323 NS | July 31, 2026 | N-PORT |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.01% | 85,082 SH | Aug. 19, 2026 | Daily |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0.01% | 8,319 SH | Aug. 19, 2026 | Daily |
| FYEE · Fidelity Greenwood Street Trust | 0.01% | 110 NS | July 31, 2026 | N-PORT |
| REVS · Columbia ETF Trust I | 0.01% | 124 NS | July 31, 2026 | N-PORT |
| IWD · iShares Trust | 0.01% | 30,627 SH | Sept. 11, 2026 | Daily |
| IJH · iShares Trust | · | 3,528,125 SH | Sept. 11, 2026 | Daily |
| IJK · iShares Trust | · | 582,451 SH | Sept. 11, 2026 | Daily |
| XJH · iShares Trust | · | 13,736 SH | Sept. 8, 2026 | Daily |
| ISCB · iShares Trust | · | 4,526 SH | Sept. 11, 2026 | Daily |
NBIX Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 36 analysts
BUY
Median target
$214.00
+49.5%
14 38.9%
Strong Buy
17 47.2%
Buy
5 13.9%
Hold
0 0.0%
Sell
0 0.0%
Strong Sell
12-Month Price Target
29 analysts · 2026-10-03Mean target $207.81 +45.1%
← Below all targets
Current price $143.18
Low$164.00
Mean$207.81
High$253.00
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| NBIX | $14.20B | 30.4 | 21.4% | 16.7% | 16.1% | · |
| INSM | $37.29B | -27.1 | 66.7% | -210.5% | -128.4% | · |
| INCY | $19.60B | 15.4 | 21.2% | 25.0% | 27.6% | · |
| UTHR | $21.27B | 17.5 | 10.6% | 41.9% | 18.7% | 87.9% |
| EXEL | $11.44B | 15.7 | 7.0% | 33.7% | 37.3% | · |
| SMMT | $13.56B | -12.1 | · | · | -235.1% | · |
| BBIO | $14.90B | -20.2 | 126.3% | -146.0% | 41.2% | · |
| TWST | $1.71B | -21.6 | 20.3% | -20.6% | -17.0% | · |
| HALO | $7.93B | 26.3 | 37.5% | 22.7% | 166.1% | · |
| MDGL | $13.30B | -45.3 | 432.1% | -30.1% | -44.4% | · |
Latest News Recent headlines mentioning this company
December 2027 Options Now Available For Neurocrine Biosciences (NBIX)
Nasdaq · 5 months, 3 weeks ago
Stock Market Today, April 6: Soleno Therapeutics Climbs After $2.9 Billion All-Cash Buyout Agreement
Nasdaq · 5 months, 3 weeks ago
Neurocrine To Acquire Soleno For $2.9 Bln Cash Deal; Soleno Stock Surges In Pre-market
Nasdaq · 5 months, 3 weeks ago
Trading Signals Recent buy/sell signals with entry price and risk/reward ratio
BLUECHIP_DIP
Stopped out
risk 1
reward 1.67
entry
$156.04
R:R 1.67
BLUECHIP_DIP
Stopped out
risk 1
reward 2.78
entry
$161.50
R:R 2.78
BLUECHIP_DIP
Expired
risk 1
reward 5.00
entry
$129.88
R:R 5.00
BLUECHIP_DIP
Stopped out
risk 1
reward 4.80
entry
$132.67
R:R 4.80
BLUECHIP_DIP
Stopped out
risk 1
reward 5.00
entry
$132.79
R:R 5.00
No open signal right now — no card is filled, and that's honest.
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Jul 31, 2026